{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:40:50Z","timestamp":1760524850962,"version":"build-2065373602"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment Programme","doi-asserted-by":"publisher","award":["14\/49\/127"],"award-info":[{"award-number":["14\/49\/127"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Vitamin D deficiency is common in patients with end stage kidney disease (ESKD) and is a strong predictor of death from cardiovascular disease, infections and cancer. Currently only 68% of patients in the UK survive 3\u00a0years or more on dialysis. Vitamin D replacement typically utilises activated (1\u03b1-hydroxylated) vitamin D compounds allowing for impaired renal activation. However, this approach increases blood calcium concentrations and may paradoxically accelerate vitamin D catabolism. Contemporary treatment guidelines recommend replacement with inactive (unhydroxylated) vitamin D<jats:sub>3<\/jats:sub> (cholecalciferol), instead relying on autocrine and paracrine vitamin D activation in target tissues. However, the impact of this approach on clinical outcomes has not yet been tested in adequately powered trials.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>The SIMPLIFIED (Survival Improvement with Cholecalciferol in Patients on Dialysis) trial will test whether supplementation with high-dose cholecalciferol improves survival. Adult dialysis patients will be recruited from one of 72 UK renal centres, by local clinicians and research nurses, and randomly assigned in a 1:1 ratio to high-dose open-label cholecalciferol or standard care, stratified by site. Trial outcomes will be captured using existing data sources including Office of National Statistics (ONS) for deaths and Hospital Episode Statistics (HES) for secondary endpoints. The primary endpoint of the trial is all-cause mortality. Key secondary endpoints include survival free from cardiovascular events, infections and cancers, and quality of life and cost-effectiveness measures utilising the Eq5D tool. Severe adverse event line listings will be generated from HES data for safety reporting. In this superiority trial, it is anticipated that approximately 4200 patients in total will need to be enrolled to observe 2200 deaths over a period of about 7\u00a0years, which will yield 90% power to demonstrate a hazard ratio of 0.87.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion<\/jats:title>\n            <jats:p>Outcomes for patients on dialysis remain very poor. The pragmatic design of this study leveraging routinely collected data streamlines trial conduct, reducing burden on patients and local site study staff. Furthermore, since cholecalciferol is a low-cost and easy to administer intervention, evidence of benefit could be readily incorporated into dialysis care across healthcare systems globally.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Trial registration<\/jats:title>\n            <jats:p>EudraCT Number: 2015-005003-88; ISRCTN Number: 15087616 (registration date 30th December 2015) (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/doi.org\/10.1186\/ISRCTN15087616\" ext-link-type=\"uri\">https:\/\/doi.org\/10.1186\/ISRCTN15087616<\/jats:ext-link>). Recruitment commenced in March 2017.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13063-025-09134-9","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:14:38Z","timestamp":1760523278000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A pragmatic, randomised, open-label, multi-centre UK registry-facilitated trial evaluating the effect of high-dose cholecalciferol on mortality in patients on dialysis: the SIMPLIFIED trial"],"prefix":"10.1186","volume":"26","author":[{"given":"Toby J. L.","family":"Humphrey","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fergus J.","family":"Caskey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David C.","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian B.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward C. F.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam P.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francis","family":"Dowling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Vencilas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Molly","family":"Cui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon J.","family":"Bond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas F.","family":"Hiemstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7438-5156","authenticated-orcid":false,"given":"Rona M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"9134_CR1","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1159\/000353324","volume":"123","author":"R Steenkamp","year":"2013","unstructured":"Steenkamp R, Shaw C, Feest T. UK Renal Registry 15th annual report: chapter 5 survival and causes of death of UK adult patients on renal replacement therapy in 2011: national and centre-specific analyses. Nephron Clin Pract. 2013;123:93\u2013123.","journal-title":"Nephron Clin Pract"},{"key":"9134_CR2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1053\/j.ajkd.2008.05.005","volume":"52","author":"M Jhamb","year":"2008","unstructured":"Jhamb M, Weisbord SD, Steel JL, Unruh M. Fatigue in patients receiving maintenance dialysis: a review of definitions, measures, and contributing factors. Am J Kidney Dis. 2008;52:353\u201365.","journal-title":"Am J Kidney Dis"},{"key":"9134_CR3","unstructured":"Department of Health. The national service framework for renal services part one: dialysis and transplantation. 2004."},{"key":"9134_CR4","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1097\/01.ASN.0000100125.21491.46","volume":"15","author":"GFM Strippoli","year":"2004","unstructured":"Strippoli GFM, Craig JC, Schena FP. The number, quality, and coverage of randomized controlled trials in nephrology. J Am Soc Nephrol. 2004;15:411\u20139.","journal-title":"J Am Soc Nephrol"},{"key":"9134_CR5","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1056\/NEJMoa065485","volume":"355","author":"AK Singh","year":"2006","unstructured":"Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med. 2006;355:2085\u201398.","journal-title":"N Engl J Med"},{"key":"9134_CR6","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","volume":"377","author":"C Baigent","year":"2011","unstructured":"Baigent C, et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181\u201392.","journal-title":"Lancet"},{"key":"9134_CR7","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","volume":"367","author":"G Chertow","year":"2012","unstructured":"The EVOLVE Trial Investigators, Chertow G, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482\u201394.","journal-title":"N Engl J Med."},{"key":"9134_CR8","first-page":"391","volume":"32","author":"R Krause","year":"2012","unstructured":"Krause R, et al. Vitamin D status and mortality of German hemodialysis patients. Anticancer Res. 2012;32:391\u20135.","journal-title":"Anticancer Res"},{"key":"9134_CR9","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","volume":"72","author":"M Wolf","year":"2007","unstructured":"Wolf M, et al. Vitamin D levels and early mortality among incident hemodialysis patients. Kidney Int. 2007;72:1004\u201313.","journal-title":"Kidney Int"},{"issue":"6","key":"9134_CR10","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2215\/CJN.10651012","volume":"8","author":"K Shaffi","year":"2013","unstructured":"Shaffi K, et al. Low 25-hydroxyvitamin D levels and cognitive impairment in hemodialysis patients. Clin J Am Soc Nephrol. 2013;8(6):979\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"key":"9134_CR11","doi-asserted-by":"publisher","first-page":"3799","DOI":"10.1093\/ndt\/gfp370","volume":"24","author":"G Jean","year":"2009","unstructured":"Jean G, Souberbielle J-C, Chazot C. Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation. Nephrol Dial Transplant. 2009;24:3799\u2013805.","journal-title":"Nephrol Dial Transplant"},{"key":"9134_CR12","doi-asserted-by":"publisher","first-page":"F8","DOI":"10.1152\/ajprenal.00336.2004","volume":"289","author":"AS Dusso","year":"2005","unstructured":"Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol. 2005;289:F8\u201328.","journal-title":"Am J Physiol Renal Physiol"},{"key":"9134_CR13","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1126\/science.1123933","volume":"311","author":"PT Liu","year":"2006","unstructured":"Liu PT, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006;311:1770\u20133.","journal-title":"Science"},{"key":"9134_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g1903","volume":"348","author":"R Chowdhury","year":"2014","unstructured":"Chowdhury R, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ. 2014;348:g1903.","journal-title":"BMJ"},{"key":"9134_CR15","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1001\/jamacardio.2017.0175","volume":"2","author":"R Scragg","year":"2017","unstructured":"Scragg R, et al. Effect of monthly high-dose vitamin D supplementation on cardiovascular disease in the vitamin D assessment study. JAMA Cardiol. 2017;2:608.","journal-title":"JAMA Cardiol"},{"key":"9134_CR16","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa1809944","volume":"380","author":"JE Manson","year":"2019","unstructured":"Manson JE, et al. Vitamin D supplements and prevention of cancer and cardiovascular disease. N Engl J Med. 2019;380:33\u201344.","journal-title":"N Engl J Med"},{"key":"9134_CR17","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1097\/MJT.0b013e3182211b3b","volume":"20","author":"A Lishmanov","year":"2013","unstructured":"Lishmanov A, Dorairajan S, Pak Y, Chaudhary K, Chockalingam A. Treatment of 25-OH vitamin D deficiency in older men with chronic kidney disease stages 3 and 4 is associated with reduction in cardiovascular events. Am J Ther. 2013;20:480\u20136.","journal-title":"Am J Ther"},{"key":"9134_CR18","first-page":"S1","volume":"76","author":"KDIGO clinical practice guideline for the diagnosis","year":"2009","unstructured":"KDIGO clinical practice guideline for the diagnosis. evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. 2009;76:S1-130.","journal-title":"Kidney Int"},{"key":"9134_CR19","doi-asserted-by":"publisher","first-page":"824","DOI":"10.7326\/0003-4819-159-12-201312170-00729","volume":"159","author":"SP Fortmann","year":"2013","unstructured":"Fortmann SP, Burda BU, Senger C, Lin JS, Whitlock EP. Vitamin and mineral supplements in the primary prevention of cardiovascular disease and cancer: an updated systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013;159:824\u201334.","journal-title":"Ann Intern Med"},{"key":"9134_CR20","volume":"3","author":"G Bjelakovic","year":"2012","unstructured":"Bjelakovic G, Nikolova D, Gluud LL, Simonetti RG, Gluud C. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2012;3:CD007176.","journal-title":"Cochrane Database Syst Rev"},{"issue":"43","key":"9134_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta18430","volume":"18","author":"TP van Staa","year":"2014","unstructured":"van Staa TP, Dyson L, McCann G, et al. The opportunities and challenges of pragmatic point-of-care randomised trials using routinely collected electronic records: evaluations of two exemplar trials. Health Technol Assess. 2014;18(43):1\u2013146.","journal-title":"Health Technol Assess"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09134-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-025-09134-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-025-09134-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:14:42Z","timestamp":1760523282000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-025-09134-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9134"],"URL":"https:\/\/doi.org\/10.1186\/s13063-025-09134-9","relation":{},"ISSN":["1745-6215"],"issn-type":[{"value":"1745-6215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"12 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics committee approval was received from Cambridge East Research Ethics Committee (REC reference: 16\/EE\/0065) on 10th March 2016.\u00a0 Written, informed consent to participate will be obtained from all participants enrolled into the SIMPLIFIED trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate {24}"}},{"value":"On completion of the trial, the data will be analysed and tabulated and an Intervention Specific Final Trial Report prepared. The results of this trial may be published or presented at scientific meetings. Authorship of final trial outputs will be assigned and funding acknowledged in accordance with guidelines set out by the International Committee of Medical Journal Editors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication {32}"}},{"value":"The authors declare that they have no research funding or honoraria in relation to this work. TFH is now an employee of Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests {28}"}}],"article-number":"415"}}